GlobeNewswire

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
23/03/2026
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months [...]
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
23/03/2026
Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments of approximately $98 [...]
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
23/03/2026
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated [...]
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
23/03/2026
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia SAN JOSE, Calif., March 23, 2026 (GLOBE [...]
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies (OTC: BSEM), a leading MedTech [...]
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
23/03/2026
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that it will be opening its [...]
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
23/03/2026
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 [...]
Philips convenes the Annual General Meeting of Shareholders 2026
23/03/2026
March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published [...]
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer
23/03/2026
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda [...]
Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
23/03/2026
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein [...]
Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment
23/03/2026
March 23, 2026 John DeFord proposed as new member of the Supervisory Board. Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board. Marc Harrison will step down [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
23/03/2026
COPENHAGEN, Denmark, March 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
23/03/2026
Accepted Abstracts Highlight Advances in AI-Driven Oncology Pipeline VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company [...]
Groundbreaking Danish research project launches to cure Parkinson’s disease
23/03/2026
A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK 26,689,872million [...]
Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
23/03/2026
Cambridge, UK, 23 rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming [...]
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
23/03/2026
New senior executives bring significant biopharma experience as Persica moves to next phase of its development London, UK, 23 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology [...]
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
23/03/2026
EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
23/03/2026
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
23/03/2026
New Rhapsido ® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx ® data build on extensive body of evidence supporting [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum